MSI-H And dMMR Market | Business Growth, Development Factors, Current and Future Trends till 2029

 For those planning market entry or expansion, this report lays out critical data and expert analysis on the msi-h and dmmr industry landscape.

MSI-H And dMMR Market Analysis & Forecast: 2025-2029

The MSI-H and dMMR market size has grown exponentially in recent years. It will grow from $6.15 billion in 2024 to $7.57 billion in 2025 at a compound annual growth rate (CAGR) of 23.0%. The growth in the historic period can be attributed to rising incidence of colorectal and endometrial cancers, expanded genetic screening programs, growing clinical adoption of MSI testing, increasing awareness of hereditary cancer syndromes, and a rise in liquid biopsy adoption.



The MSI-H and dMMR market size is expected to see exponential growth in the next few years. It will grow to $17.26 billion in 2029 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, expanding applications of next-generation sequencing, rising healthcare expenditure in oncology, growing clinical trials for immune checkpoint inhibitors, and regulatory support for companion diagnostics. Major trends in the forecast period include the integration of artificial intelligence in diagnostic workflows, partnerships between pharma and diagnostic companies, the development of multiplex biomarker panels, advances in immunotherapy, and a shift toward pan-cancer biomarker testing.



Get your free sample today:

MSI-H And dMMR Market Share & Opportunities Report 2025 Sample



What Are The Factors Driving The MSI-H And dMMR Market?

The rising prevalence of cancer is expected to propel the growth of the MSI-H and dMMR market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is primarily due to aging populations, as the risk of developing cancer increases significantly with age because of the cumulative effect of genetic mutations and prolonged exposure to risk factors over time. MSI-H and dMMR are used in cancer to identify tumors with high mutation rates due to defects in DNA repair mechanisms. These biomarkers help guide immunotherapy decisions, as such tumors are more likely to respond to immune checkpoint inhibitors, and they also provide insight into prognosis and potential genetic syndromes. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, in 2023, an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths were expected in the United States. These numbers are projected to rise in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, highlighting a continuing increase in cancer incidence and mortality. Therefore, the rising prevalence of cancer is driving the growth of the MSI-H and dMMR market.



What Segments Are Covered In The MSI-H And dMMR Market Report?

The msi-h and dmmr market covered in this report is segmented –



1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare



Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies



What Are The Main Trends, Positively Impacting The Growth Of MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are focusing on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves using two or more treatment modalities, commonly immunotherapy agents such as checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to enhance treatment response, overcome resistance, and improve survival outcomes in patients with tumors that exhibit high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing treatment options for this challenging cancer subtype. This approval marks a significant milestone in the treatment of MSI-H and dMMR cancers, as it provides a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, addressing the unmet medical needs in this patient population.



Which Are The Major Players Operating In The Global MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.



View the full msi-h and dmmr market report here:

MSI-H And dMMR Market Share & Opportunities Report 2025



MSI-H And dMMR Market Regional Insights:

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.



Contact Us:



The Business Research Company



Market Research Reports



Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267



Email: info@tbrc.info





Follow Us On:



LinkedIn: The Business Research Company | LinkedIn